Share Price and Basic Stock Data
Last Updated: January 16, 2026, 12:20 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Zota Health Care Ltd operates in the pharmaceuticals sector, with its stock currently priced at ₹1,337 and a market capitalization of ₹4,436 Cr. The company has shown a fluctuating sales performance over the past quarters, with revenues reported at ₹39 Cr in September 2022, rising to ₹45 Cr by September 2023, and projected to reach ₹67 Cr by September 2024. This upward trend indicates a growing demand for its products. However, total revenues for FY 2025 are expected to significantly escalate to ₹292 Cr, reflecting a robust growth trajectory compared to ₹139 Cr in FY 2023. The company has managed to maintain a relatively stable operational performance, with total expenses for FY 2025 expected at ₹298 Cr, suggesting a focus on scaling operations efficiently. Historical data reveals that Zota’s sales growth has been inconsistent, as seen in its quarterly revenues, showcasing both peaks and troughs, which may pose challenges in sustaining investor confidence.
Profitability and Efficiency Metrics
Zota Health Care’s profitability metrics have displayed volatility, with a reported net profit of -₹62 Cr for the trailing twelve months (TTM). This decline is stark compared to the prior fiscal year’s net profit of -₹6 Cr, indicating significant operational challenges. The operating profit margin (OPM) stood at a mere 5% as of the latest reporting, reflecting a downward trend from previous periods, while the return on equity (ROE) was reported at 36%, highlighting potential profitability concerns. The interest coverage ratio (ICR) of -0.33x indicates that the company is struggling to meet its interest obligations, raising red flags about financial sustainability. Additionally, the cash conversion cycle (CCC) has extended to 219 days, which is considerably high and suggests inefficiencies in working capital management. These factors collectively indicate that while Zota aims for growth, its current operational profitability and efficiency metrics require urgent attention to ensure long-term viability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Zota Health Care reveals a total debt of ₹181 Cr against reserves of ₹285 Cr, indicating a manageable debt level relative to its equity base. The total liabilities have escalated to ₹606 Cr, reflecting the company’s increasing operational scale. The price-to-book value (P/BV) ratio at 10.31x suggests that the market values the company significantly higher than its book value, which may indicate investor optimism despite current losses. Furthermore, the current ratio of 1.83x and quick ratio of 0.77x illustrate a reasonable liquidity position, although the quick ratio is below the ideal benchmark of 1. This liquidity profile may pose challenges in meeting short-term obligations if sales do not stabilize. The total debt-to-equity ratio stands at 0.02x, indicating a conservative approach to leveraging. Collectively, these financial ratios reflect a company in a challenging phase that needs to enhance its profitability while maintaining financial stability.
Shareholding Pattern and Investor Confidence
Zota Health Care’s shareholding pattern indicates a predominant promoter holding of 55.81% as of September 2025, down from 68.12% in December 2022, which may suggest a gradual dilution of control. Institutional investors, including foreign institutional investors (FIIs) and domestic institutional investors (DIIs), have increased their stakes to 3.49% and 4.95%, respectively, showcasing a slight uptick in institutional confidence. The public shareholding currently stands at 35.75%, which reflects a diverse shareholder base. The increase in the number of shareholders to 11,855 from 7,956 in December 2022 indicates growing interest in the stock, despite its recent financial struggles. However, the declining promoter holding could be interpreted as a lack of confidence in the company’s near-term prospects, which may deter potential investors. This dynamic underscores the importance of Zota Health Care addressing its operational inefficiencies to regain investor trust and stabilize its market position.
Outlook, Risks, and Final Insight
Zota Health Care’s future outlook hinges on its ability to navigate current operational challenges and improve profitability metrics. The anticipated growth in revenues to ₹292 Cr for FY 2025 presents an opportunity for recovery, but the persistent net losses and declining OPM raise concerns about sustainable growth. Key risks include the company’s high cash conversion cycle of 219 days, which could strain liquidity if not addressed, and the negative interest coverage ratio, which complicates debt management. On the strength side, the company’s solid reserve base of ₹285 Cr provides a cushion for operational adjustments, and the increasing institutional interest may serve as a potential stabilizing factor. Ultimately, Zota must focus on streamlining operations and enhancing profitability to capitalize on its revenue growth potential and restore investor confidence in a challenging market environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 207/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,021.01 Cr | 1,119.28 | 52.44 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 35 | 37 | 39 | 45 | 47 | 50 | 56 | 67 | 72 | 97 | 104 | 129 |
| Expenses | 34 | 35 | 36 | 37 | 41 | 44 | 51 | 58 | 68 | 78 | 95 | 100 | 123 |
| Operating Profit | 5 | 0 | 1 | 1 | 4 | 3 | -1 | -1 | -1 | -6 | 2 | 4 | 6 |
| OPM % | 12% | 0% | 3% | 3% | 10% | 7% | -3% | -2% | -1% | -8% | 3% | 4% | 5% |
| Other Income | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 |
| Depreciation | 3 | 3 | 4 | 3 | 5 | 5 | 7 | 8 | 10 | 11 | 14 | 15 | 19 |
| Profit before tax | 2 | -3 | -3 | -3 | -1 | -3 | -10 | -12 | -13 | -18 | -14 | -13 | -14 |
| Tax % | 58% | -4% | -15% | 1% | 49% | 7% | -27% | 5% | -4% | 2% | -10% | 5% | 13% |
| Net Profit | 1 | -3 | -3 | -3 | -2 | -3 | -7 | -13 | -12 | -19 | -13 | -14 | -16 |
| EPS in Rs | 0.36 | -1.28 | -1.05 | -1.13 | -0.64 | -1.14 | -2.68 | -4.79 | -4.41 | -6.78 | -4.50 | -4.81 | -5.20 |
Last Updated: December 28, 2025, 11:32 am
Below is a detailed analysis of the quarterly data for Zota Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 104.00 Cr. (Jun 2025) to 129.00 Cr., marking an increase of 25.00 Cr..
- For Expenses, as of Sep 2025, the value is 123.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 100.00 Cr. (Jun 2025) to 123.00 Cr., marking an increase of 23.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 6.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 5.00%. The value appears strong and on an upward trend. It has increased from 4.00% (Jun 2025) to 5.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Jun 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Jun 2025) to 19.00 Cr., marking an increase of 4.00 Cr..
- For Profit before tax, as of Sep 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from -13.00 Cr. (Jun 2025) to -14.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 13.00%. The value appears to be increasing, which may not be favorable. It has increased from 5.00% (Jun 2025) to 13.00%, marking an increase of 8.00%.
- For Net Profit, as of Sep 2025, the value is -16.00 Cr.. The value appears to be declining and may need further review. It has decreased from -14.00 Cr. (Jun 2025) to -16.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is -5.20. The value appears to be declining and may need further review. It has decreased from -4.81 (Jun 2025) to -5.20, marking a decrease of 0.39.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:22 am
| Metric | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 38 | 50 | 56 | 85 | 95 | 106 | 131 | 139 | 180 | 292 | 402 |
| Expenses | 21 | 33 | 43 | 47 | 77 | 90 | 105 | 116 | 132 | 173 | 298 | 395 |
| Operating Profit | 4 | 5 | 6 | 8 | 8 | 5 | 1 | 15 | 7 | 8 | -6 | 7 |
| OPM % | 14% | 13% | 13% | 15% | 9% | 5% | 1% | 11% | 5% | 4% | -2% | 2% |
| Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 4 |
| Interest | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 5 | 11 | 12 |
| Depreciation | 0 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 12 | 20 | 43 | 59 |
| Profit before tax | 3 | 3 | 5 | 6 | 8 | 4 | -0 | 12 | -5 | -16 | -58 | -60 |
| Tax % | 34% | 33% | 33% | 33% | 29% | 29% | -41% | 28% | 23% | -11% | -2% | |
| Net Profit | 2 | 2 | 3 | 4 | 6 | 3 | -0 | 9 | -6 | -14 | -57 | -62 |
| EPS in Rs | 2.17 | 1.43 | 1.85 | 2.12 | 2.26 | 1.12 | -0.09 | 3.54 | -2.29 | -5.55 | -19.70 | -21.29 |
| Dividend Payout % | 0% | 50% | 38% | 34% | 32% | 90% | -1,170% | 42% | -44% | -18% | -5% |
YoY Net Profit Growth
| Year | 2011-2012 | 2014-2015 | 2019-2020 | 2020-2021 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 33.33% | -50.00% | -100.00% | -166.67% | -133.33% | -307.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | 33.33% | -83.33% | -50.00% | -66.67% | 33.33% | -173.81% |
Zota Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2011-2012 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 25% |
| 3 Years: | 31% |
| TTM: | 72% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -139% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 55% |
| 3 Years: | 72% |
| 1 Year: | 93% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -15% |
| 3 Years: | -24% |
| Last Year: | -36% |
Last Updated: September 5, 2025, 1:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:15 am
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 10 | 12 | 14 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 31 |
| Reserves | 5 | 3 | 4 | 4 | 51 | 44 | 42 | 64 | 55 | 64 | 195 | 285 |
| Borrowings | 3 | 6 | 5 | 5 | 0 | 0 | 0 | 15 | 45 | 95 | 140 | 181 |
| Other Liabilities | 5 | 10 | 14 | 17 | 21 | 20 | 19 | 35 | 33 | 43 | 76 | 109 |
| Total Liabilities | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 606 |
| Fixed Assets | 8 | 10 | 9 | 8 | 10 | 15 | 14 | 29 | 62 | 103 | 185 | 251 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 7 |
| Investments | 0 | 0 | 0 | 0 | 16 | 14 | 10 | 33 | 8 | 5 | 54 | 92 |
| Other Assets | 12 | 19 | 26 | 32 | 63 | 59 | 61 | 77 | 85 | 116 | 193 | 256 |
| Total Assets | 20 | 29 | 35 | 40 | 90 | 88 | 85 | 139 | 158 | 228 | 439 | 606 |
Below is a detailed analysis of the balance sheet data for Zota Health Care Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 2.00 Cr..
- For Reserves, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 195.00 Cr. (Mar 2025) to 285.00 Cr., marking an increase of 90.00 Cr..
- For Borrowings, as of Sep 2025, the value is 181.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 140.00 Cr. (Mar 2025) to 181.00 Cr., marking an increase of 41.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 109.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Mar 2025) to 109.00 Cr., marking an increase of 33.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 606.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 439.00 Cr. (Mar 2025) to 606.00 Cr., marking an increase of 167.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 185.00 Cr. (Mar 2025) to 251.00 Cr., marking an increase of 66.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 92.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 92.00 Cr., marking an increase of 38.00 Cr..
- For Other Assets, as of Sep 2025, the value is 256.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 256.00 Cr., marking an increase of 63.00 Cr..
- For Total Assets, as of Sep 2025, the value is 606.00 Cr.. The value appears strong and on an upward trend. It has increased from 439.00 Cr. (Mar 2025) to 606.00 Cr., marking an increase of 167.00 Cr..
Notably, the Reserves (285.00 Cr.) exceed the Borrowings (181.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.00 | -1.00 | 1.00 | 3.00 | 8.00 | 5.00 | 1.00 | 0.00 | -38.00 | -87.00 | -146.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 71 | 79 | 77 | 95 | 112 | 99 | 102 | 73 | 55 | 50 |
| Inventory Days | 122 | 141 | 134 | 175 | 208 | 139 | 140 | 121 | 183 | 201 | 281 |
| Days Payable | 77 | 90 | 0 | 0 | 104 | 82 | 77 | 78 | 116 | 126 | 113 |
| Cash Conversion Cycle | 120 | 123 | 212 | 251 | 199 | 169 | 161 | 145 | 140 | 131 | 219 |
| Working Capital Days | 102 | 70 | 78 | 80 | 175 | 152 | 143 | 108 | 111 | 75 | 100 |
| ROCE % | 20% | 32% | 6% | -2% | 15% | -2% | -7% | -17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -20.68 | -5.59 | -2.29 | 3.58 | -0.09 |
| Diluted EPS (Rs.) | -19.06 | -5.47 | -2.29 | 3.58 | -0.09 |
| Cash EPS (Rs.) | -4.73 | 2.22 | 2.46 | 5.00 | 1.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 78.11 | 34.81 | 31.94 | 35.62 | 26.99 |
| Revenue From Operations / Share (Rs.) | 102.31 | 69.83 | 55.63 | 52.14 | 43.48 |
| PBDIT / Share (Rs.) | -1.28 | 3.37 | 3.69 | 6.53 | 0.76 |
| PBIT / Share (Rs.) | -16.36 | -4.40 | -1.06 | 5.07 | -0.52 |
| PBT / Share (Rs.) | -20.13 | -6.25 | -1.86 | 4.94 | -0.14 |
| Net Profit / Share (Rs.) | -19.81 | -5.55 | -2.29 | 3.54 | -0.08 |
| NP After MI And SOA / Share (Rs.) | -19.70 | -5.55 | -2.29 | 3.54 | -0.08 |
| PBDIT Margin (%) | -1.25 | 4.82 | 6.63 | 12.52 | 1.76 |
| PBIT Margin (%) | -15.99 | -6.30 | -1.90 | 9.72 | -1.20 |
| PBT Margin (%) | -19.67 | -8.95 | -3.35 | 9.47 | -0.34 |
| Net Profit Margin (%) | -19.36 | -7.94 | -4.12 | 6.78 | -0.19 |
| NP After MI And SOA Margin (%) | -19.25 | -7.94 | -4.12 | 6.78 | -0.19 |
| Return on Networth / Equity (%) | -25.21 | -15.94 | -7.18 | 9.93 | -0.31 |
| Return on Capital Employeed (%) | -13.84 | -7.35 | -2.26 | 12.36 | -1.90 |
| Return On Assets (%) | -12.84 | -6.28 | -3.65 | 6.40 | -0.24 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.02 | 0.16 | 0.00 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.87 | 0.93 | 0.94 | 1.25 | 1.23 |
| Current Ratio (X) | 1.83 | 1.51 | 2.08 | 2.14 | 3.36 |
| Quick Ratio (X) | 0.77 | 0.78 | 1.05 | 1.33 | 1.81 |
| Inventory Turnover Ratio (X) | 3.67 | 0.26 | 0.49 | 0.71 | 0.75 |
| Dividend Payout Ratio (NP) (%) | -4.85 | -18.01 | -65.37 | 28.24 | -1175.68 |
| Dividend Payout Ratio (CP) (%) | -20.76 | 45.05 | 61.02 | 20.00 | 82.97 |
| Earning Retention Ratio (%) | 104.85 | 118.01 | 165.37 | 71.76 | 1275.68 |
| Cash Earning Retention Ratio (%) | 120.76 | 54.95 | 38.98 | 80.00 | 17.03 |
| Interest Coverage Ratio (X) | -0.33 | 1.82 | 3.62 | 51.22 | 17.16 |
| Interest Coverage Ratio (Post Tax) (X) | -4.26 | -2.00 | -1.46 | 28.78 | -10.27 |
| Enterprise Value (Cr.) | 2311.57 | 1240.13 | 707.78 | 746.47 | 338.81 |
| EV / Net Operating Revenue (X) | 7.89 | 6.87 | 5.06 | 5.69 | 3.17 |
| EV / EBITDA (X) | -630.73 | 142.37 | 76.17 | 45.44 | 179.81 |
| MarketCap / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| Retention Ratios (%) | 104.85 | 118.01 | 165.37 | 71.75 | 1275.68 |
| Price / BV (X) | 10.31 | 13.63 | 8.82 | 8.35 | 5.13 |
| Price / Net Operating Revenue (X) | 7.87 | 6.80 | 5.07 | 5.71 | 3.19 |
| EarningsYield | -0.02 | -0.01 | -0.01 | 0.01 | 0.00 |
After reviewing the key financial ratios for Zota Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -20.68. This value is below the healthy minimum of 5. It has decreased from -5.59 (Mar 24) to -20.68, marking a decrease of 15.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is -19.06. This value is below the healthy minimum of 5. It has decreased from -5.47 (Mar 24) to -19.06, marking a decrease of 13.59.
- For Cash EPS (Rs.), as of Mar 25, the value is -4.73. This value is below the healthy minimum of 3. It has decreased from 2.22 (Mar 24) to -4.73, marking a decrease of 6.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 78.11. It has increased from 34.81 (Mar 24) to 78.11, marking an increase of 43.30.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.31. It has increased from 69.83 (Mar 24) to 102.31, marking an increase of 32.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.28. This value is below the healthy minimum of 2. It has decreased from 3.37 (Mar 24) to -1.28, marking a decrease of 4.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is -16.36. This value is below the healthy minimum of 0. It has decreased from -4.40 (Mar 24) to -16.36, marking a decrease of 11.96.
- For PBT / Share (Rs.), as of Mar 25, the value is -20.13. This value is below the healthy minimum of 0. It has decreased from -6.25 (Mar 24) to -20.13, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -19.81. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.81, marking a decrease of 14.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -19.70. This value is below the healthy minimum of 2. It has decreased from -5.55 (Mar 24) to -19.70, marking a decrease of 14.15.
- For PBDIT Margin (%), as of Mar 25, the value is -1.25. This value is below the healthy minimum of 10. It has decreased from 4.82 (Mar 24) to -1.25, marking a decrease of 6.07.
- For PBIT Margin (%), as of Mar 25, the value is -15.99. This value is below the healthy minimum of 10. It has decreased from -6.30 (Mar 24) to -15.99, marking a decrease of 9.69.
- For PBT Margin (%), as of Mar 25, the value is -19.67. This value is below the healthy minimum of 10. It has decreased from -8.95 (Mar 24) to -19.67, marking a decrease of 10.72.
- For Net Profit Margin (%), as of Mar 25, the value is -19.36. This value is below the healthy minimum of 5. It has decreased from -7.94 (Mar 24) to -19.36, marking a decrease of 11.42.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -19.25. This value is below the healthy minimum of 8. It has decreased from -7.94 (Mar 24) to -19.25, marking a decrease of 11.31.
- For Return on Networth / Equity (%), as of Mar 25, the value is -25.21. This value is below the healthy minimum of 15. It has decreased from -15.94 (Mar 24) to -25.21, marking a decrease of 9.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is -13.84. This value is below the healthy minimum of 10. It has decreased from -7.35 (Mar 24) to -13.84, marking a decrease of 6.49.
- For Return On Assets (%), as of Mar 25, the value is -12.84. This value is below the healthy minimum of 5. It has decreased from -6.28 (Mar 24) to -12.84, marking a decrease of 6.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.16 (Mar 24) to 0.02, marking a decrease of 0.14.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has decreased from 0.93 (Mar 24) to 0.87, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.83. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.83, marking an increase of 0.32.
- For Quick Ratio (X), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 1. It has decreased from 0.78 (Mar 24) to 0.77, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.67. This value is below the healthy minimum of 4. It has increased from 0.26 (Mar 24) to 3.67, marking an increase of 3.41.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -4.85. This value is below the healthy minimum of 20. It has increased from -18.01 (Mar 24) to -4.85, marking an increase of 13.16.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is -20.76. This value is below the healthy minimum of 20. It has decreased from 45.05 (Mar 24) to -20.76, marking a decrease of 65.81.
- For Earning Retention Ratio (%), as of Mar 25, the value is 104.85. This value exceeds the healthy maximum of 70. It has decreased from 118.01 (Mar 24) to 104.85, marking a decrease of 13.16.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 120.76. This value exceeds the healthy maximum of 70. It has increased from 54.95 (Mar 24) to 120.76, marking an increase of 65.81.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.33. This value is below the healthy minimum of 3. It has decreased from 1.82 (Mar 24) to -0.33, marking a decrease of 2.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -4.26. This value is below the healthy minimum of 3. It has decreased from -2.00 (Mar 24) to -4.26, marking a decrease of 2.26.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,311.57. It has increased from 1,240.13 (Mar 24) to 2,311.57, marking an increase of 1,071.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 3. It has increased from 6.87 (Mar 24) to 7.89, marking an increase of 1.02.
- For EV / EBITDA (X), as of Mar 25, the value is -630.73. This value is below the healthy minimum of 5. It has decreased from 142.37 (Mar 24) to -630.73, marking a decrease of 773.10.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For Retention Ratios (%), as of Mar 25, the value is 104.85. This value exceeds the healthy maximum of 70. It has decreased from 118.01 (Mar 24) to 104.85, marking a decrease of 13.16.
- For Price / BV (X), as of Mar 25, the value is 10.31. This value exceeds the healthy maximum of 3. It has decreased from 13.63 (Mar 24) to 10.31, marking a decrease of 3.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.87. This value exceeds the healthy maximum of 3. It has increased from 6.80 (Mar 24) to 7.87, marking an increase of 1.07.
- For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Zota Health Care Ltd:
- Net Profit Margin: -19.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -13.84% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -25.21% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -4.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.77
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.44)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -19.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Zota House, 2/896, Surat Gujarat 395002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ketankumar Chandulal Zota | Non Executive Chairman |
| Mr. Moxesh Ketanbhai Zota | Managing Director |
| Mr. Laxmi Kant Sharma | Executive Director |
| Mr. Himanshu Muktilal Zota | Whole Time Director |
| Mr. Kamlesh Rajnikant Zota | Whole Time Director |
| Mr. Viren Manukant Zota | Whole Time Director |
| Mrs. Jaysheeben Nileshkumar Mehta | Ind. Non-Executive Director |
| Mrs. Bhumi Maulik Doshi | Ind. Non-Executive Director |
| Dr.(Mrs.) Varsaben Gaurang Mehta | Ind. Non-Executive Director |
| CA. Dhaval Chandubhai Patwa | Ind. Non-Executive Director |
| CA. Vitrag Sureshkumar Modi | Ind. Non-Executive Director |
| Dr. Dhiren Prafulbhai Shah | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Zota Health Care Ltd?
Zota Health Care Ltd's intrinsic value (as of 17 January 2026) is ₹232.38 which is 82.51% lower the current market price of ₹1,329.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹4,408 Cr. market cap, FY2025-2026 high/low of ₹1,740/752, reserves of ₹285 Cr, and liabilities of ₹606 Cr.
What is the Market Cap of Zota Health Care Ltd?
The Market Cap of Zota Health Care Ltd is 4,408 Cr..
What is the current Stock Price of Zota Health Care Ltd as on 17 January 2026?
The current stock price of Zota Health Care Ltd as on 17 January 2026 is ₹1,329.
What is the High / Low of Zota Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Zota Health Care Ltd stocks is ₹1,740/752.
What is the Stock P/E of Zota Health Care Ltd?
The Stock P/E of Zota Health Care Ltd is .
What is the Book Value of Zota Health Care Ltd?
The Book Value of Zota Health Care Ltd is 103.
What is the Dividend Yield of Zota Health Care Ltd?
The Dividend Yield of Zota Health Care Ltd is 0.07 %.
What is the ROCE of Zota Health Care Ltd?
The ROCE of Zota Health Care Ltd is 17.0 %.
What is the ROE of Zota Health Care Ltd?
The ROE of Zota Health Care Ltd is 36.0 %.
What is the Face Value of Zota Health Care Ltd?
The Face Value of Zota Health Care Ltd is 10.0.